Bristol-Myers Squibb (BMY) analyst forecast and price target
Analyst forecast
Consensus of 31 analyst ratings
Based on 12 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Equal-Weight | $60.00 from $65.00 | Oct 13, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $53.00 from $59.00 | Oct 8, 2026 |
| Morgan Stanley | Maintained | Underweight | $41.00 from $40.00 | Oct 7, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $59.00 from $73.00 | Oct 5, 2026 |
| Piper Sandler | Maintained | Overweight | $82.00 from $75.00 | Sep 16, 2026 |
| HSBC | Maintained | Hold | $65.00 from $60.00 | Sep 10, 2026 |
| Argus Research | Upgraded | Hold → Buy | $75.00 | Aug 5, 2026 |
| Citigroup | Maintained | Neutral | $70.00 from $66.00 | Aug 3, 2026 |
| Truist Securities | Maintained | Buy | $70.00 from $65.00 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $75.00 from $72.00 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $65.00 from $60.00 | Jul 31, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $59.00 from $54.00 | Jul 31, 2026 |
| JP Morgan | Maintained | Overweight | $73.00 from $67.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Sector Perform | $64.00 from $60.00 | Jul 31, 2026 |
| B of A Securities | Maintained | Buy | $66.00 from $67.00 | Jul 10, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $54.00 | Jul 6, 2026 |
| B of A Securities | Maintained | Buy | $67.00 from $68.00 | Apr 9, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $54.00 from $45.00 | Apr 8, 2026 |
| Guggenheim | Maintained | Buy | $72.00 | Apr 8, 2026 |
| HSBC | Maintained | Hold | $60.00 from $53.00 | Mar 17, 2026 |
Frequently asked questions
What is the price target for BMY stock?
The average 12-month analyst price target for Bristol-Myers Squibb (BMY) is $65.58, with a high estimate of $82.00 and a low of $41.00, across 12 analysts.
Is BMY a buy, sell, or hold?
Analysts covering Bristol-Myers Squibb currently average a Hold rating: 11 buy, 18 hold and 2 sell, from 31 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BMY?
The average price target of $65.58 implies 9.76% upside from the last price of $59.75.
What is the latest analyst rating on BMY?
On Oct 13, 2026, Wells Fargo maintained Bristol-Myers Squibb at Equal-Weight with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.